Anti-PD1 therapy works by activating cell immunity, therefore to what extent an SCID mouse would be able to respond to this therapy if they are immuno compromised to begin with?
I think you're right. PD1 is a T-cell inhibitor. SCID mice don't have those. You can't target something that's not there. Makes me wish every cancer researcher was as lucid (chemotherapy + immunotherapy, anyone?)
Thanks for the lucid, one of the things I've learned in this business is to criticize your own research.
Do you have any experience growing tumors in non SCID mice?
It is not very clear to me from your question whether you want to induce orthotopic melanoma model by carcinogen or ectopic tumor by injecting melanoma cells? I think mice of C57/BL6J background can be good choice for both the case. You can not use SCID mice if you are considering T cell response.
I've routinely used C57/BL6J in combination with the B16F1 or B16F10 (more metastatic and unstable than B16F1) cell-lines depending on what we were looking at.
i think you can use Female C57BL/6 mice, 6 to 8 weeks old .you must inject B16-F10 melanoma cells (1x105) into the right flank of each mouse subcutaneously to achive an appropriate model of melanoma.
Actually, most Antibody-mediated cellular cytotoxicity is dependent on NK activity, and not T cells. CD8+ T cells are directly cytotoxic, killing cells without antibody present. SCID mice have normal NK activity.
Years ago, I generated a line of SCID-beige mice - the beige mutation inhibits NK activity. Those mice were NK deficient. I was hoping for a better host for xenogeneic grafts, but that was a marginal improvement at best..
I personally have never grown melanomas in SCID mice, but I expect it has been done. I suggest checking the literature.
- Badges
- Science topic
- Similar topics
- Medicine
- Disease
- Disease Models
- Animal Models
- Rodent Models
- Mouse Models